{'fraction_non_alphanumeric': 0.02881844380403458, 'fraction_numerical': 0.01729106628242075, 'mean_word_length': 4.791666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Central venous catheter thrombosis and the fibrin sleeve: unraveling the mystery

Venous thromboembolism (VTE) is the second most common cause of death among outpatients with cancer 1. Twenty to thirty percent of all first episodes of VTE occur in patients with cancer, and cancer patients carry a 4-7-fold increased risk of venous thrombosis (DVT) compared with the general population2. While the overall cumulative incidence of DVT in patients with cancer is 1-8% 2, the incidence of clinically overt or venographically evident DVT in patients with central venous catheters (CVCs) may rise as high as 28 and 66%, respectively 3. 
 
This article is protected by copyright. All rights reserved.